-
Professor Li Junmin The advantages are fully displayed, and the future can be expected, and the unique mechanism of ropsitine helps to build a new pattern of ITP diagnosis and treatment
Time of Update: 2022-10-01
From July 9 to 13, 2022, the 30th International Society for Thrombotic and Hemostatic Society (ISTH) announced a number of research advances in the field of hematology. Considerable progress has been
-
How to treat survival longer after surgery for early lung cancer?
Time of Update: 2022-10-01
In another study, for stage II to IIIA non-small cell lung cancer, if tumor cells have greater than 1% PD-L1 expression, then after complete resection and adjuvant chemotherapy, giving the PD-L1 inhibitor altelizumab can improve progression-free survival.
-
2022CSH Professor Zhao Weiying: Talk about the present and future of DLBCL, and be grateful to remember every moment of the 17th National Hematology Academic Conference of the Chinese Medical Association
Time of Update: 2022-10-01
Medical Pulse Communication: Domestic and foreign researchers have been actively exploring DLBCL treatment options and strategies, your team has also been committed to studying DLBCL better curing options, can you please talk about the development of the field of DLBCL treatment in recent years and the prospect of future treatment trends of DLBCL?Professor Zhao WeiyingIn the past, clinically, patients were initially stratified by IPI analysis, then treated with R-CHOP regimens, and transplanted in subsequent recurrences.
-
2022CSH Talents gather to climb the "peak" of blood scholarship! The 17th National Hematology Academic Conference of the Chinese Medical Association was successfully concluded
Time of Update: 2022-10-01
Professor Ni Heyu made a wonderful reportUnder the co-chairmanship of Professor Fu Rong of the General Hospital of Tianjin Medical University and Professor Liu Daihong of the General Hospital of the People's Liberation Army of Chinese, Professor Hu Yu of the Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology reported on the development of gene therapy for coagulation diseases.
-
Express $700 million to help develop anti-cancer bispecific nanoantibodies! Seagen reached a partnership
Time of Update: 2022-10-01
▲If you have any business needs, please long press to scan the QR code above, or▎Editor of WuXi AppTec content teamSeagen today announced an exclusive licensing agreement with LAVA Therapeutics, which will jointly develop, manufacture and commercialize the in-development bispecific VHH LAVA-1223.
-
WIREs │ Yu Meng, Wang Yongxia team of Southern Medical University: A nano-drug delivery strategy to regulate the tumor microenvironment is used to overcome tumor multidrug resistance
Time of Update: 2022-10-01
Associate Professor Yu Meng of Southern Medical University and Yongxia Wang, Director of the Department of Mammary Science, Dongguan Hospital Affiliated to Southern Medical University, reviewed the relationship between the main characteristics of tumor microenvironment and drug resistance, and summarized the current application of different microenvironment regulatory strategies in the treatment of drug-resistant tumors (Figure 1).
-
ESMO former "research" newsletter | Olaparil maintenance therapy for non-embryonic BRCA mutation platinum-sensitive recurrent ovarian cancer progression
Time of Update: 2022-10-01
The 2022 European Society for Internal Oncology (ESMO) Annual Meeting was held in Paris from September 9 to 13 local time. As the world's first approved PARP inhibitor, Olapari has undoubtedly brought
-
【2022 ESMO】Keeping up with the Times│ Discussion on the Management of Oligometastatic Hormone-Sensitive Prostate Cancer
Time of Update: 2022-10-01
Although the PEACE-1[7] and ARASENS[8] studies suggest that the triple regimen has a better survival benefit than the dual regimen of ADT combined chemotherapy, speaker Professor Silke Gillessen argues that for patients with omHSPC, she prefers to choose new endocrine drugs instead of chemotherapy; Because the PEACE-1 and ARASENS studies included a small number of patients with low tumors or oligometastases, the conclusions were insufficient to support clinical treatment options.
-
Lancet: Phase 1 tumor clinical trial, patients benefit more and more in recent years
Time of Update: 2022-10-01
The researchers analyzed patient-level data from 2000 to 2019 in the Phase 1 solid tumor trial initiated by the NCI Cancer Therapy Evaluation Program of the National Cancer Institute (NIH), focusing on high-level toxicity and objective tumor response rates.
-
Liver cancer innovation "Damo Unlimited" | hepatobiliary surgery "big coffee" reviews 2022 ESMO blockbuster progress
Time of Update: 2022-10-01
The 2022 ESMO Academic Event came to an end, and many heavy research data in the field of liver cancer treatment were brilliantly displayed, lighting up the speculative light of clinical diagnosis and
-
【2022 ESMO】The latest progress of PSMA in the diagnosis and treatment of prostate cancer
Time of Update: 2022-10-01
The study included a total of 79 mCRPC patients who had received 177Lu-PSMA radioligand therapy (RLT) between 2016 and 2021, with a median age of 82 years, and the study evaluated PSA response rate, PFS, OS outcomes, and safety signals.
-
5 hmC in cfDNA can be used as a non-invasive diagnostic marker for gliomas
Time of Update: 2022-10-01
Professor Mao Ying and others from the Department of Neurosurgery of Huashan Hospital affiliated to Fudan University reported that Professor Mao Ying's team recruited 111 patients with glioma and matching healthy individuals, applied 5hmC-Seal technology to detect the expression level of 5hmC in circulating free DNA (cfDNA), and analyzed its characteristics in terms of glioma diagnosis grading, gene mutation, pathological diagnosis and related biology.
-
Replimune publishes the results of clinical trials of oncolytic viruses and double-fists to treat advanced cancer
Time of Update: 2022-10-01
RP2 Oncolytic Virus Anti-Cancer Mechanism RP2 is a genetically engineered selective replication of herpes simplex virus type 1 (HSV-1), on which Replimune adds codon-optimized human granulocyte-macrophage colony-stimulating factor (GM-CSF), R sequence missing gibbon leukemia virus surface glycoprotein (GALV-GP R-), and CTLA-4 antibody-like molecule.
-
Express $65 million to help develop a new generation of PARP1 inhibitors, Merck partnered
Time of Update: 2022-10-01
▲If you have any business needs, please long press to scan the QR code above, or▎Editor of WuXi AppTec content teamNerviano Medical Sciences (NMS) recently announced a collaboration and licensing agreement with Merck & Co.
-
Most people are in the middle and advanced stages of diagnosis at the time of diagnosis, what are the treatments for non-small cell lung cancer?
Time of Update: 2022-10-01
The NTRK-targeted drug NTRK gene mutation is not common in non-small cell lung cancer, and only a small number of NSCLC patients carry this mutation, which can lead to abnormal cell growth.
-
Big change in the pathological classification of ovarian tumors! It will change the treatment landscape
Time of Update: 2022-10-01
*For medical professionals onlyExperts will take you to analyze the pathological typing and molecular classification of ovarian cancer, as well as the prognosis to determine new progressAt the recent
-
Pancreatic cancer is advanced once discovered? How should it be treated?
Time of Update: 2022-10-01
First, surgical treatment: surgery is the only way to cure the cure, pancreatic cancer if found relatively early, limited location, can be radical resection, is currently the most effective method, for obstructive jaundice, and can not be removed pancreatic cancer, you can choose gallbladder or bile duct jejunal anastomosis, intervention under stent implantation, thereby reducing jaundice, improve the patient's liver function, improve the quality of life.
-
Professor Ke Xiaoyan's team reveals the relationship between the genetic background of patients with relapsed refractory DLBCL and the efficacy of CAR-T: exploring the potential and challenges of CAR-T in the real world
Time of Update: 2022-10-01
To further explore the factors that may influence CAR-T treatment, Dr. Shi Hui, from Professor Kexiaoyan Hu Kai of Beijing Boren Hospital, published an article titled "Genetic landscapes and curative effect of CAR T-cell immunotherapy in relapse and refractory DLBCL" in the journal Blood Advances patients' paper provides a new perspective for researchers in the specialized field of hematologic lymphoma.
-
Gao Junying and Li Guorong, Shandong Normal University, et al.: Translation control of tumor proteins to promote cancer invasion and migration and its potential clinical prospects
Time of Update: 2022-10-01
Keyword group:Translation-controlled tumor protein (TCTP); invasion; Migration; Cancer; Clinical drugsAuthor: Junying GAO, Yan MA, Guiwen YANG, Guorong LIThis article references format:Junying GAO, Yan MA, Guiwen YANG, Guorong LI.
-
Good article collection! American Society for Cancer Research Releases 2022 Progress Report on Cancer (with PDF)
Time of Update: 2022-10-01
▲August 2021 - July 2022 FDA newly approved anti-cancer therapy (Source: AACR official website)Among them, targeted therapies can more precisely target cancer cells in tumors, making the treatment more effective and reducing toxicity to healthy tissue.
